Dr. Wen-Hsuan Chang, AcuraStem’s Head of Target Validation to present at the 33nd International Symposium on ALS/MND being held virtually on December 6-9, 2022. Dr. Chang will detail AcuraStem’s development program leveraging its best-in-class  iNeuroRx® platform, composed of patient-derived disease models that accurately recapitulate UNC13A pathology, to develop novel and potent UNC13A antisense oligonucleotide (ASO) drug candidates. UNC13A is one of the most significant genetic risk factors for ALS and FTD.

AcuraStem (acurastem.com), a patient-based drug discovery platform company developing novel therapeutics for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases, announced the results of extensive preclinical studies on its lead program, AS-202, for ALS patients. The data were presented at the Motor Neuron Disease Association 32nd International Symposium on ALS/MND on December 9, by AcuraStem’s Head of Research, Wen-Hsuan Chang, Ph.D.

AcuraStem will present posters at the 32nd International Symposium on ALS/MND.

The CMT Research Foundation today announced it has partnered with AcuraStem, a patient-based drug discovery platform company, and Dr. Alessandra Bolino, to test a new drug to fight  CMT4B1. Dr. Alessandra Bolino, who will lead the research and testing, is a renowned expert in CMT and head of the Human Inherited Neuropathies Unit at the prestigious research hospital Ospedale San Raffaele in Milan. 

AcuraStem has received an Amyotrophic Lateral Sclerosis Research Pro-gram (ALSRP) Therapeutic Development Award from the Department of Defense, Congressionally Directed Medical Research Programs (CDMRP) totaling $1 million.

“We are excited to add our collaborator Dr. Robert Bowser to our advisory board. Bob is a worldwide leader in ALS biomarker development. His expertise will be critical as we look to validate key, CNS-specific, mechanistic biomarkers for our PIKFYVE programs,” said Sam Alworth, co-founder and chief executive officer of AcuraStem.

AcuraStem was honored to once again partner with Team Nanci and the ALS Association Golden West Chapter in the fight against ALS as a sponsor of the 17th Annual Los Angeles County Walk to Defeat ALS® on Sunday, November 3, at Exposition Park in Los Angeles.

AcuraStem announced today that the company has triggered Phase II funding worth $3 million from its Fast Track Small Business Innovation Research (SBIR) grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH).

MDA has awarded an MVP grant totaling $300,000 over two years to AcuraStem to support preclinical development of a novel small molecule therapeutic for ALS.

CMT Research Foundation announced today it has entered into a collaborative research partnership with AcuraStem to test thousands of compounds aimed at producing effective treatments for Charcot-Marie-Tooth disease.

AcuraStem will join in the fight against ALS as a sponsor of the 16th Annual Los Angeles County Walk to Defeat ALS® on Sunday, November 4, at Exposition Park in Los Angeles. The team will walk with “Team Nanci” and be on hand at the AcuraStem booth to talk to patients and families affected by Amyotrophic Lateral Sclerosis (ALS) about its mission and research underway.

AcuraStem has announced the members of its Scientific Board of Advisors comprised of PhDs, professors, tech entrepreneurs, and successful drug company veterans.

AcuraStem announces the addition of Monica Zhou, Ph.D. to their team as Principal Scientist. Zhou is in charge of industrializing the expansion of AcuraStem’s groundbreaking iNeuroRx platform and its multiple applications, ensuring their accuracy and efficiency.

AcuraStem a fast-growing and innovative biotech company located in Monrovia, California, has been awarded a $3.7 million Small Business Innovation Research (SBIR) Fast-Track grant (#R44NS105156) by the National Institute of Neurological Disorders and Stroke (NINDS) to continue research for the development of a small molecule therapeutic, “AS2015”, focused on treating patients with the genetic form of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) caused by expansion repeats in the gene C9ORF72.

AcuraStem is pleased to announce that it has been selected as a finalist in the 2018 Start-Up Stadium event at the BIO International Convention, June 4-7 in Boston.

The award recognizes Dr. Ichida's "pioneering work to convert patients’ skin cells into disease-affected neural cells, enabling them to screen thousands of drug-like compounds in search of potential therapeutics that could slow or stop ALS."

AcuraStem has been awarded a $225 thousand Phase I SBIR grant by the National Institute on Aging (NIA), part of the National Institutes of Health. The grant will fund continued research of AcuraStem’s laboratory models of age-associated ALS, supporting the evaluation of different molecular methods to create motor neurons in the laboratory that more accurately reproduce the ALS disease state in aged patients.

The Governor’s Office of Business and Economic Development (GO-Biz) announced that the California Competes Tax Credit (CCTC) committee approved $69 million in tax credits for 90 companies projected to create 6,236 jobs and make $1.2 billion worth of new capital equipment investments across California.